US20020192725A1 - Relation of apolipoprotein E genotype and estrogen deprivation in alzheimer's disease - Google Patents
Relation of apolipoprotein E genotype and estrogen deprivation in alzheimer's disease Download PDFInfo
- Publication number
- US20020192725A1 US20020192725A1 US10/180,669 US18066902A US2002192725A1 US 20020192725 A1 US20020192725 A1 US 20020192725A1 US 18066902 A US18066902 A US 18066902A US 2002192725 A1 US2002192725 A1 US 2002192725A1
- Authority
- US
- United States
- Prior art keywords
- subject
- apoe4
- disease
- alzheimer
- determining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 54
- 239000000262 estrogen Substances 0.000 title claims abstract description 36
- 229940011871 estrogen Drugs 0.000 title claims abstract description 32
- 102100029470 Apolipoprotein E Human genes 0.000 title description 5
- 101710095339 Apolipoprotein E Proteins 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 50
- 108700028369 Alleles Proteins 0.000 claims abstract description 47
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims abstract description 31
- 238000009164 estrogen replacement therapy Methods 0.000 claims abstract description 23
- 230000003247 decreasing effect Effects 0.000 claims abstract description 15
- 238000012216 screening Methods 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims description 13
- 108010025628 Apolipoproteins E Proteins 0.000 claims description 12
- 102000013918 Apolipoproteins E Human genes 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 10
- 108010029485 Protein Isoforms Proteins 0.000 claims description 9
- 102000001708 Protein Isoforms Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 230000001076 estrogenic effect Effects 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 3
- 230000002357 endometrial effect Effects 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 230000004043 responsiveness Effects 0.000 claims description 2
- 238000009802 hysterectomy Methods 0.000 abstract description 6
- 230000009245 menopause Effects 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 description 18
- 239000013543 active substance Substances 0.000 description 10
- 239000006187 pill Substances 0.000 description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 239000007933 dermal patch Substances 0.000 description 6
- 229960005309 estradiol Drugs 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000004874 Synaptophysin Human genes 0.000 description 4
- 108090001076 Synaptophysin Proteins 0.000 description 4
- 210000001947 dentate gyrus Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004565 granule cell Anatomy 0.000 description 4
- 108010060215 Apolipoprotein E3 Proteins 0.000 description 3
- 102000008128 Apolipoprotein E3 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000000718 cholinopositive effect Effects 0.000 description 3
- 210000001787 dendrite Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 208000015756 familial Alzheimer disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 210000001176 projection neuron Anatomy 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 101150037123 APOE gene Proteins 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 101150066038 E4 gene Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 210000005110 dorsal hippocampus Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004295 hippocampal neuron Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- RWBRUCCWZPSBFC-RXRZZTMXSA-N (20S)-20-hydroxypregn-4-en-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](O)C)[C@@]1(C)CC2 RWBRUCCWZPSBFC-RXRZZTMXSA-N 0.000 description 1
- ISHXLNHNDMZNMC-VTKCIJPMSA-N (3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C\1 ISHXLNHNDMZNMC-VTKCIJPMSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- 208000022099 Alzheimer disease 2 Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- -1 alkali metal salts Chemical class 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003687 estradiol congener Substances 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
- 229950008385 estrone sulphate Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229940012028 ethynodiol diacetate Drugs 0.000 description 1
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
- 229960005352 gestodene Drugs 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 mestranol Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002667 norelgestromin Drugs 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 229960001858 norethynodrel Drugs 0.000 description 1
- 229960000417 norgestimate Drugs 0.000 description 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Definitions
- the present invention concerns methods of screening for Alzheimer's disease susceptibility in subjects, along with methods of classifying susceptible individuals for treatment and methods of treating Alzheimer's disease.
- AD Alzheimer's disease
- APOE apolipoprotein E
- the APOE E4 allele is a risk factor for late-onset, familial and sporadic AD while the APOE3 and E2 alleles are either neutral (E3) or protective (E2).
- Another risk factor is sex; both the incidence and prevalence of AD is greater in females than in males.
- the methods involve directly or indirectly detecting the presence or absence of an apolipoprotein E type 4 (ApoE4) isoform or DNA, encoding ApoE4 in the subject.
- ApoE4 indicates the subject is afflicted with Alzheimer's disease or at risk of developing Alzheimer's disease. This basic finding has led to a number of developments in the Alzheimer's disease field.
- ACT alphal-antichymotrypsin
- U.S. Pat. No. 5,935,781 to J. Poirer assigned to McGill University.
- This patent describes a method for the identification of human subjects responsive to cholinomimetic therapy. The method comprises determining the absence of apolipoprotein E4 (apoE4) alleles in a biological sample of the patient, where the absence of at least one apoE4 allele indicates a predisposition to respond to cholinomimetic therapy. Methods of administering cholinomimetics to such identified subjects are also described.
- apoE4 apolipoprotein E4
- AD Alzheimer's disease
- a first aspect of the present invention is a method of screening (e.g., diagnosing or prognosing) a subject for risk of developing Alzheimer's disease.
- the method comprises: (a) determining the presence of at least one ApoE4 allele in a subject, and (b) determining the presence or absence of decreased estrogen levels in said subject.
- the presence of at least one ApoE4 allele (and particularly two ApoE4 alleles) in combination with decreased estrogen levels in said subject indicating said subject is at greater risk of developing Alzheimer's disease (e.g., as compared to subjects with at corresponding number of ApoE4 alleles, but who do not have decreased estrogen levels).
- a second aspect of the present invention is a method for screening a subject for responsiveness to estrogen replacement therapy for the treatment of Alzheimer's disease.
- the method comprises determining the presence of at least on ApoE4 allele in the subject.
- the presence of at least one apoE4 gene allele allele (and particularly two ApoE4 alleles) indicates that the subject will receive greater benefit from estrogen replacement therapy that a subject who does not carry at least one ApoE4 allele allele (and particularly two ApoE4 alleles).
- the presence of at least one ApoE4 allele indicates a predisposition, or potential, of that subject to beneficially respond to estrogen replacement therapy (e.g., a greater likelihood that that subject will beneficially respond to estrogen replacement therapy as compared to a subject that does not carry at least one ApoE4 allele).
- a third aspect of the present invention is a method for treating a subject for Alzheimer's disease.
- the method comprises: (a) determining the presence of at least one ApoE4 allele in said subject allele (and particularly two ApoE4 alleles); and then (b) administering estrogen replacement therapy to that subject (i.e., a subject carrying one or two ApoE4 alleles) in an Alzheimer's disease treatment effective amount.
- a fourth aspect of the present invention is a method of treating a human female subject for Alzheimer's disease, where that subject carries at least one ApoE4 allele allele (and particularly two ApoE4 alleles).
- the method comprises administering estrogen replacement therapy to the subject in an Alzheimer's disease treatment effective amount.
- the estrogen replacement therapy is initiated to a susceptible subject as described above prior to the onset of menopause, or at least concurrently with the onset of menopause, or is initiated concurrently with a hysterectomy.
- the object in this embodiment is to reduce, inhibit, or eliminate a gap in estrogen levels, or the time for which the subject is exposed to decreased estrogen levels, so that the risk of early neuronal cell death in that patient is reduced, and the time of onset of Alzheimer's disease is delayed, and/or the progression of that disease is slowed.
- a fifth aspect of the present invention is the use of an estrogen replacement therapy active agent for the preparation of a medicament for the treatment of Alzheimer's disease.
- FIG. 1 shows that there is no difference in spine density in the dorsal blade of the dentate gyrus in ApoE3 as compared to ApoE4 mice, comparing Sham OVX and OVX mice.
- FIG. 2 illustrates that CA1 apical dendrite spine density is significantly decreased in female ApoE4 mice deprived of estrogen.
- FIG. 3 shows that stratum radiatum synapthophysin immunoreactivity is significantly decreased in ApoE4 mice deprived of estrogen.
- ApoE4 refers to apolipoprotein E4.
- Estrogen replacement therapy refers to a long-term therapy in which estrogen or estrogenic active agents are administered to a subject continuously over an extended period of time (e.g., a month, a year, or more) to maintain sustained blood levels of the active agent to combat the effects of menopause or hysterectomy (e.g., loss of calcium from bone and increased incidience of classical osteoporotic fractures of the forearm and hip, ischemic heart disease, etc.). The administration may be daily or periodically.
- “Decreased estrogen levels” as used herein means that the subject has estrogen levels indicating that the subject is a candidate for or should receive estrogen replacement therapy (e.g., an estrogen level at a post-menopausal rather than a pre-menopausal level; an estrogen level at a post-hysterectomy rather than a pre-hysterectomy level in a pre-menopausal woman).
- estrogen replacement therapy e.g., an estrogen level at a post-menopausal rather than a pre-menopausal level; an estrogen level at a post-hysterectomy rather than a pre-hysterectomy level in a pre-menopausal woman.
- Subjects suitable for the present invention include those who have not previously been diagnosed as afflicted with Alzheimer's disease, those which have previously been determined to be at risk of developing Alzheimer's disease, and those who have been initially diagnosed as being afflicted with Alzheimer's disease where confirming information is desired, or where a focused treatment option is desired.
- patients diagnosed or determined to be afflicted with dementia particularly patients who had previously been clinically normal who are determined to be afflicted with a progressive dementia, are suitable subjects.
- the present invention may be employed in detecting both familial Alzheimer's disease (late onset and early onset) as well as sporadic Alzheimer's disease. Many Alzheimer's disease patients encountered in practice have no obvious family history and have been classified as sporadic.
- Late-onset Alzheimer's disease is the classification usually used if the disease is diagnosed to occur after the age of 65 in humans.
- the present invention is particularly useful in identifying patients who would benefit from the early administration of an estrogen replacement therapy.
- Subjects suitable for the present invention are, in general, human subjects, and are preferably female subjects.
- the step of detecting the presence or absence of ApoE4 or of DNA encoding such isoform may be carried out either directly or indirectly by any suitable means.
- a variety of techniques are known to those skilled in the art. All generally involve the step of collecting a sample of biological material containing either DNA or ApoE from the subject, and then detecting whether or not the subject possesses ApoE4 or DNA encoding such isoform from that sample.
- the detecting step may be carried out by collecting an ApoE sample from the subject (for example, from cerebrospinal fluid, or any other fluid or tissue containing ApoE), and then determining the presence or absence of an ApoE4 isoform in the ApoE sample (e.g., by-isoelectric focusing or immunoassay).
- the detecting step may be carried out by collecting a biological sample containing DNA from the subject, and then determining the presence or absence of DNA encoding an ApoE4 isoform in the biological sample. Any biological sample which contains the DNA of that subject may be employed, including tissue samples and blood samples, with blood cells being a particularly convenient source.
- Patients may be selected for treatment by the methods of the present invention based upon knowledge of the ApoE4 profile of that individual patient (i.e., the presence of one or two ApoE4 alleles).
- the ApoE profile may be obtained in the manner described above. Of course, it is not necessary that such screening or profiling be at the same time or place, or by the same individual, as making the selection for therapy, so long as the selection is based upon this information.
- Estrogen replacement therapy may be carried out by any suitable means. All typically involve administering an active agent such as estrogen or an estrogen analog (typically a steroid that has estrogen activity) to the subject in an estrogen replacement therapy effective amount, which is commensurate with an Alzheimer's disease treatment effective amount (e.g., an amount effective to delay the onset of AD, slow the progression of AD, etc.). Any suitable route of administration may be employed, including, but not limited to, oral administration, aerosol administration to airway surfaces, intravenous injection, subcutaneous injection, intramuscular injection, transdermal administration (e.g., a patch), etc. Oral and transdermal formulations are currently preferred. Numerous estrogen replacement therapy preparations and protocols are known, including but not limited to those described in U.S.
- Suitable active agents for estrogen replacement therapy include, but are not limited to, natural and synthetic estrogens such as conjugated equine estrogen, ethinyl estradiol, micronized estradiol, 17 ⁇ estradiol, mestranol, estradiol valerate, 11-nitrato estradiol, 7- ⁇ -methyl-11-nitrato-estradiol, piperazine estrone sulfate, quinestranol, and 8,9-dehydroestereone (particularly alkali metal salts and sulfate esters thereof). See, e.g., U.S. Pat. No. 5,422,119 at column 6; U.S. Pat. No. 5,288,717.
- all active agents may be prepared as a pharmaceutically acceptable salt or ester, in accordance with known techniques,
- the progestin component may be any progestationally active compound, including but not limited to progsterone, 17-hydroxyprogesterone, dihydroprogesterone, medroxyprogesterone acetate, norethindrone, norethindrone acetate, norethynodrel, ethynodioldiacetate, norgesterel, levo-norgesterel, gestodene, delta-15-levonorgesterel, norgestimate, 17-deacetyl norgestimate, nomegestereol, nesterone, desogesterel and 3-keto-desogesteral. See, e.g., U.S. Pat. No. 5,422,119 at column 6.
- a pharmaceutical formulation or medicament for estrogen replacement therapy is prepared by bringing an effective of the active agent into contact with a pharmaceutically acceptable carrier, such as lactose or talc (for an oral administration), intimately admixing the two, and forming (when necessary) the mixture into a suitable unit dosage form such as a patch for transdermal administration or a tablet, dragee, capsule or pill for an oral dosage form.
- a pharmaceutically acceptable carrier such as lactose or talc (for an oral administration)
- suitable unit dosage form such as a patch for transdermal administration or a tablet, dragee, capsule or pill for an oral dosage form.
- the amount of active agent administered will depend upon factors such as the specific active agent, the age, weight and condition of the subject, the route of administration, etc.
- the estrogenic active agent may be administered in an a amount of from 0.3 to 1.2 mg daily for orally administered conjugated equine estrogen; or from about 25 ⁇ g/day to about 150 ⁇ g/day of transdermal ⁇ -estradiol.
- Examples of commercially available estrogen preparations include: AloraTM (skin patch), ClimaraTM (skin patch), EstradermTM (skin patch), FemPatchTM (skin patch), EstraceTM (pill or skin patch), EstrabTM (pill), MensetTM (pill), OgenTM (pill), Ortho-estTM (pill), and PremarinTM (pill).
- estrogen/progestin combination formulations examples include, but are not limited to, CombipatchTM (skin patch) and PremproTM (pill).
- estrogen levels may be directly or indirectly determined in a subject by measuring serum estradiol levels in accordance with known techniques, or by measuring vaginal or urethral pH levels, as described in U.S. Pat. No. 5,916,176 to Caillouette. Of course, decreased estrogen levels may be inferred from menopause or hysterectomy.
- mice created from the C57B1/6J line with the human isoforms of APOE3 and APOE4 were used (P. -T. Xu et al., Neurobiol. Dis. 3, 229-235 (1996). Three sibling pairs were obtained for each group. At 14 months of age, one member of each pair was ovariectomized (OVX) while the other member received a sham OVX surgery.
- OVX ovariectomized
- Hippocampal CA1 pyramidal cells and dentate granule cells were injected intracellularly with Lucifer yellow in accordance with known techniques (G. Einstein, J. Neurosci. Meth. 26, 95-103 (1988)). At least three slices from the dorsal hippocampus were injected per animal, with 10-15 granule cells and CA1 neurons injected per slice.
- Table 1 below shows that there is no difference in the optical density of SYN-IR for the molecular layers of the dorsal blade of the dentate gyrus.
- Table 1 shows that there is no difference in the optical density of SYN-IR for the molecular layers of the dorsal blade of the dentate gyrus.
- Table 1 shows that there is no difference in the optical density of SYN-IR for the molecular layers of the dorsal blade of the dentate gyrus.
- Table 1 shows that there is no difference in the optical density of SYN-IR for the molecular layers of the dorsal blade of the dentate gyrus.
- FIG. 1 shows that there is no difference in spine density in the dorsal blade of the dentate gyrus in ApoE3 as compared to ApoE4 mice, comparing Sham OVX and OVX mice.
- FIG. 2 illustrates that CA1 apical dendrite spine density is significantly decreased in female ApoE4 mice deprived of estrogen.
- FIG. 3 shows that stratum radiatum synapthophysin immunoreactivity is significantly decreased in ApoE4 mice deprived of estrogen.
- mice carrying the APOE4 gene had a significant decrease in spine density on the apical dendrites of CA1 pyramidal neurons when compared to sham OVX sibs. In contrast, mice carrying the APOE3 gene had no change in spine density of CA1 pyramidal neurons when compared to sham OVX sibs.
- mice carrying the APOE4 gene had a significant decrease in the density of SYN-IR in the stratum radiatum when compared to sham OVX sibs. In contrast, mice carrying the APOE3 gene had no change in the density of SYN-IR in the stratum radiatum when compared to sham OVX sibs.
- mice carrying the APOE3 and E4 gene had no change in spine density of dorsal blade dentate granule cells when compared to sham OVX sibs.
- Mice carrying the APOE3 and E4 gene had no change in the density of SYN-IR in the molecular layer of the dentate when compared to sham OVX sibs.
Abstract
A method of screening a subject for risk of developing Alzheimer's disease comprises determining the presence of at least one ApoE4 allele in a subject, and determining the presence or absence of decreased estrogen levels in said subject (e.g., due to previous or impending menopause or hysterectomy). The presence of at least one ApoE4 allele (and particularly two ApoE4 alleles) in combination with decreased estrogen levels in said subject indicating said subject is at greater risk of developing Alzheimer's disease (e.g., as compared to subjects with at corresponding number of ApoE4 alleles, but who do not have decreased estrogen levels), and that the subject will receive greater benefit from estrogen replacement therapy in treating Alzheimer's disease than a subject who does not carry one or two ApoE4 alleles.
Description
- [0001] This invention was made with government support under Grant Number 5 T32 AG00029 from the National Institutes of Health. The government has certain rights to this invention.
- The present invention concerns methods of screening for Alzheimer's disease susceptibility in subjects, along with methods of classifying susceptible individuals for treatment and methods of treating Alzheimer's disease.
- Alzheimer's disease (AD) is marked by a devastating decrease in cognitive ability which is correlated with a decline in the number of synapses in the hippocampus and neocortex. One of the risk factors for development of AD is the gene coding for the E4 allele of a lipid carrier protein, apolipoprotein E (APOE, gene). The APOE E4 allele is a risk factor for late-onset, familial and sporadic AD while the APOE3 and E2 alleles are either neutral (E3) or protective (E2). Another risk factor is sex; both the incidence and prevalence of AD is greater in females than in males.
- U.S. Pat. No. 5,508,167 to A. Roses et al., assigned to Duke University, discloses methods of diagnosing or prognosing Alzheimer's disease in a subject. The methods involve directly or indirectly detecting the presence or absence of an apolipoprotein E type 4 (ApoE4) isoform or DNA, encoding ApoE4 in the subject. The presence of ApoE4 indicates the subject is afflicted with Alzheimer's disease or at risk of developing Alzheimer's disease. This basic finding has led to a number of developments in the Alzheimer's disease field.
- For example, U.S. Pat. No. 5,773,220 to S. DeKosy and M. Kamboh, assigned to the University of Pittsburgh, describes a method for screening for the risk of developing Alzheimer's disease in a subject by detecting the presence or absence of the ApoE allele and the presence or absence of the alphal-antichymotrypsin (ACT) allele. The presence of two ACT/A alleles, in conjunction with the presence of one or two ApoE4 alleles, is said to indicate an increased risk for Alzheimer's disease.
- In addition, U.S. Pat. No. 5,935,781 to J. Poirer, assigned to McGill University. This patent describes a method for the identification of human subjects responsive to cholinomimetic therapy. The method comprises determining the absence of apolipoprotein E4 (apoE4) alleles in a biological sample of the patient, where the absence of at least one apoE4 allele indicates a predisposition to respond to cholinomimetic therapy. Methods of administering cholinomimetics to such identified subjects are also described.
- While the identification of ApoE4 as a risk factor for Alzheimer's disease has led to a number of new developments in the field, AD remains a complex disease for which treatment is difficult and the ultimate prognosis is poor. Accordingly, there remains a need for new ways to screen for AD, classify patients for appropriate AD treatment, and treat AD.
- A first aspect of the present invention is a method of screening (e.g., diagnosing or prognosing) a subject for risk of developing Alzheimer's disease. The method comprises: (a) determining the presence of at least one ApoE4 allele in a subject, and (b) determining the presence or absence of decreased estrogen levels in said subject. The presence of at least one ApoE4 allele (and particularly two ApoE4 alleles) in combination with decreased estrogen levels in said subject indicating said subject is at greater risk of developing Alzheimer's disease (e.g., as compared to subjects with at corresponding number of ApoE4 alleles, but who do not have decreased estrogen levels).
- A second aspect of the present invention is a method for screening a subject for responsiveness to estrogen replacement therapy for the treatment of Alzheimer's disease. The method comprises determining the presence of at least on ApoE4 allele in the subject. The presence of at least one apoE4 gene allele allele (and particularly two ApoE4 alleles) indicates that the subject will receive greater benefit from estrogen replacement therapy that a subject who does not carry at least one ApoE4 allele allele (and particularly two ApoE4 alleles). Alternatively stated, the presence of at least one ApoE4 allele indicates a predisposition, or potential, of that subject to beneficially respond to estrogen replacement therapy (e.g., a greater likelihood that that subject will beneficially respond to estrogen replacement therapy as compared to a subject that does not carry at least one ApoE4 allele).
- A third aspect of the present invention is a method for treating a subject for Alzheimer's disease. The method comprises: (a) determining the presence of at least one ApoE4 allele in said subject allele (and particularly two ApoE4 alleles); and then (b) administering estrogen replacement therapy to that subject (i.e., a subject carrying one or two ApoE4 alleles) in an Alzheimer's disease treatment effective amount.
- A fourth aspect of the present invention is a method of treating a human female subject for Alzheimer's disease, where that subject carries at least one ApoE4 allele allele (and particularly two ApoE4 alleles). The method comprises administering estrogen replacement therapy to the subject in an Alzheimer's disease treatment effective amount.
- In a particularly preferred embodiment, the estrogen replacement therapy is initiated to a susceptible subject as described above prior to the onset of menopause, or at least concurrently with the onset of menopause, or is initiated concurrently with a hysterectomy. The object in this embodiment is to reduce, inhibit, or eliminate a gap in estrogen levels, or the time for which the subject is exposed to decreased estrogen levels, so that the risk of early neuronal cell death in that patient is reduced, and the time of onset of Alzheimer's disease is delayed, and/or the progression of that disease is slowed.
- A fifth aspect of the present invention is the use of an estrogen replacement therapy active agent for the preparation of a medicament for the treatment of Alzheimer's disease.
- The foregoing and other objects and aspects of the present invention are explained in detail in the drawings herein and the specification set forth below.
- FIG. 1 shows that there is no difference in spine density in the dorsal blade of the dentate gyrus in ApoE3 as compared to ApoE4 mice, comparing Sham OVX and OVX mice.
- FIG. 2 illustrates that CA1 apical dendrite spine density is significantly decreased in female ApoE4 mice deprived of estrogen.
- FIG. 3 shows that stratum radiatum synapthophysin immunoreactivity is significantly decreased in ApoE4 mice deprived of estrogen.
- Terms and phrases used herein have their ordinary meaning in the art, as further explained below.
- “ApoE4” refers to apolipoprotein E4.
- “Concurrently” as used herein means at the same time or sufficiently close in time that substantially the same physiological effect is achieved.
- “Estrogen replacement therapy” as used herein refers to a long-term therapy in which estrogen or estrogenic active agents are administered to a subject continuously over an extended period of time (e.g., a month, a year, or more) to maintain sustained blood levels of the active agent to combat the effects of menopause or hysterectomy (e.g., loss of calcium from bone and increased incidience of classical osteoporotic fractures of the forearm and hip, ischemic heart disease, etc.). The administration may be daily or periodically.
- “Decreased estrogen levels” as used herein means that the subject has estrogen levels indicating that the subject is a candidate for or should receive estrogen replacement therapy (e.g., an estrogen level at a post-menopausal rather than a pre-menopausal level; an estrogen level at a post-hysterectomy rather than a pre-hysterectomy level in a pre-menopausal woman).
- Subjects suitable for the present invention include those who have not previously been diagnosed as afflicted with Alzheimer's disease, those which have previously been determined to be at risk of developing Alzheimer's disease, and those who have been initially diagnosed as being afflicted with Alzheimer's disease where confirming information is desired, or where a focused treatment option is desired. For example, patients diagnosed or determined to be afflicted with dementia, particularly patients who had previously been clinically normal who are determined to be afflicted with a progressive dementia, are suitable subjects. Thus, the present invention may be employed in detecting both familial Alzheimer's disease (late onset and early onset) as well as sporadic Alzheimer's disease. Many Alzheimer's disease patients encountered in practice have no obvious family history and have been classified as sporadic. However, genetic factors in early- and late-onset of familial Alzheimer's disease (FAD) are well documented. Late-onset Alzheimer's disease is the classification usually used if the disease is diagnosed to occur after the age of 65 in humans. The present invention is particularly useful in identifying patients who would benefit from the early administration of an estrogen replacement therapy. Subjects suitable for the present invention are, in general, human subjects, and are preferably female subjects.
- The step of detecting the presence or absence of ApoE4 or of DNA encoding such isoform (including the number of alleles for ApoE4) may be carried out either directly or indirectly by any suitable means. A variety of techniques are known to those skilled in the art. All generally involve the step of collecting a sample of biological material containing either DNA or ApoE from the subject, and then detecting whether or not the subject possesses ApoE4 or DNA encoding such isoform from that sample. For example, the detecting step may be carried out by collecting an ApoE sample from the subject (for example, from cerebrospinal fluid, or any other fluid or tissue containing ApoE), and then determining the presence or absence of an ApoE4 isoform in the ApoE sample (e.g., by-isoelectric focusing or immunoassay). In the alternative, the detecting step may be carried out by collecting a biological sample containing DNA from the subject, and then determining the presence or absence of DNA encoding an ApoE4 isoform in the biological sample. Any biological sample which contains the DNA of that subject may be employed, including tissue samples and blood samples, with blood cells being a particularly convenient source. Numerous techniques for detecting the presence of one or two ApoE4 alleles in a subject are known, including but not limited to those described in U.S. Pat. No. 5,508,167 to Roses et al., U.S. Pat. No. 5,773,220 to S. DeKosy and M. Kamboh, and U.S. Pat. No. 5,935,781 to Poirer (applicants specifically intend that the disclosures of all United States patent references cited herein be incorporated herein by reference).
- Patients may be selected for treatment by the methods of the present invention based upon knowledge of the ApoE4 profile of that individual patient (i.e., the presence of one or two ApoE4 alleles). The ApoE profile may be obtained in the manner described above. Of course, it is not necessary that such screening or profiling be at the same time or place, or by the same individual, as making the selection for therapy, so long as the selection is based upon this information.
- Estrogen replacement therapy may be carried out by any suitable means. All typically involve administering an active agent such as estrogen or an estrogen analog (typically a steroid that has estrogen activity) to the subject in an estrogen replacement therapy effective amount, which is commensurate with an Alzheimer's disease treatment effective amount (e.g., an amount effective to delay the onset of AD, slow the progression of AD, etc.). Any suitable route of administration may be employed, including, but not limited to, oral administration, aerosol administration to airway surfaces, intravenous injection, subcutaneous injection, intramuscular injection, transdermal administration (e.g., a patch), etc. Oral and transdermal formulations are currently preferred. Numerous estrogen replacement therapy preparations and protocols are known, including but not limited to those described in U.S. Pat. Nos. 5,922,349; 5,897,539; 5,565,199; 5,468,736; 5,422,119; 5,288,717; and 5,023,084, the disclosures of all of which are incorporated by reference herein in their entirety. Other agents, such as progesterone (or progestin) in a hormone replacement therapy effective amount, may be administered along with the estrogen to provide a combination therapy, if desired (typically to reduce undesirable side-effects of estrogen monotherapy, as such estrogenic endometrial proliferation and corresponding risk of endometrial cancer).
- Suitable active agents for estrogen replacement therapy include, but are not limited to, natural and synthetic estrogens such as conjugated equine estrogen, ethinyl estradiol, micronized estradiol, 17β estradiol, mestranol, estradiol valerate, 11-nitrato estradiol, 7-α-methyl-11-nitrato-estradiol, piperazine estrone sulfate, quinestranol, and 8,9-dehydroestereone (particularly alkali metal salts and sulfate esters thereof). See, e.g., U.S. Pat. No. 5,422,119 at column 6; U.S. Pat. No. 5,288,717. Of course, all active agents may be prepared as a pharmaceutically acceptable salt or ester, in accordance with known techniques,
- The progestin component may be any progestationally active compound, including but not limited to progsterone, 17-hydroxyprogesterone, dihydroprogesterone, medroxyprogesterone acetate, norethindrone, norethindrone acetate, norethynodrel, ethynodioldiacetate, norgesterel, levo-norgesterel, gestodene, delta-15-levonorgesterel, norgestimate, 17-deacetyl norgestimate, nomegestereol, nesterone, desogesterel and 3-keto-desogesteral. See, e.g., U.S. Pat. No. 5,422,119 at column 6.
- In general, a pharmaceutical formulation or medicament for estrogen replacement therapy is prepared by bringing an effective of the active agent into contact with a pharmaceutically acceptable carrier, such as lactose or talc (for an oral administration), intimately admixing the two, and forming (when necessary) the mixture into a suitable unit dosage form such as a patch for transdermal administration or a tablet, dragee, capsule or pill for an oral dosage form.
- The amount of active agent administered will depend upon factors such as the specific active agent, the age, weight and condition of the subject, the route of administration, etc. For example, the estrogenic active agent may be administered in an a amount of from 0.3 to 1.2 mg daily for orally administered conjugated equine estrogen; or from about 25 μg/day to about 150 μg/day of transdermal β-estradiol.
- Examples of commercially available estrogen preparations include: Alora™ (skin patch), Climara™ (skin patch), Estraderm™ (skin patch), FemPatch™ (skin patch), Estrace™ (pill or skin patch), Estrab™ (pill), Menset™ (pill), Ogen™ (pill), Ortho-est™ (pill), and Premarin™ (pill).
- Examples of commercially available estrogen/progestin combination formulations include, but are not limited to, Combipatch™ (skin patch) and Prempro™ (pill).
- Where necessary, estrogen levels may be directly or indirectly determined in a subject by measuring serum estradiol levels in accordance with known techniques, or by measuring vaginal or urethral pH levels, as described in U.S. Pat. No. 5,916,176 to Caillouette. Of course, decreased estrogen levels may be inferred from menopause or hysterectomy.
- The present invention is illustrated in greater detail in the following non-limiting examples.
- This example explored whether the interaction of the ApoE4 risk factor and the estrogen risk factor might exacerbate the pathology associated with AD in a putative animal model of AD. To explore this possibility, we compared spine and synapse density in two populations of hippocampal neurons in 15-month-old human transgenic APOE4 and APOE3 mice ovariectomized (OVX) or sham OVX mice at 14 months of age. CA1 pyramidal neurons are one of the most susceptible populations of neurons in AD, while dentate granule cells are less vulnerable.
- Animals and Surgery.
- Female transgenic mice created from the C57B1/6J line with the human isoforms of APOE3 and APOE4 were used (P. -T. Xu et al.,Neurobiol. Dis. 3, 229-235 (1996). Three sibling pairs were obtained for each group. At 14 months of age, one member of each pair was ovariectomized (OVX) while the other member received a sham OVX surgery.
- Tissue Preparation.
- At 15 months of age, all animals were euthanized, their brains removed and cut along the midline. Each brain was immersion-fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (PB), pH 7.4, at room temperature (RT). After 140 minutes, the left hemisphere was removed and rinsed in 0.1 M PB. Using a vibratome, sagittal slices of 300 microns were collected in 0.1 M PB and stored at 4° C. until intracellular injection with Lucifer yellow. The right hemisphere was immersion-fixed for 48 hours at 4° C., embedded in paraffin, and sectioned sagittally into 8 micron slices that were mounted on slides in preparation for synaptophysin immunohistochemistry (SYN-IR).
- Lucifer Yellow Injections and Immunoreactivity.
- Hippocampal CA1 pyramidal cells and dentate granule cells were injected intracellularly with Lucifer yellow in accordance with known techniques (G. Einstein,J. Neurosci. Meth. 26, 95-103 (1988)). At least three slices from the dorsal hippocampus were injected per animal, with 10-15 granule cells and CA1 neurons injected per slice.
- After injection, slices were rinsed in PB and post-fixed overnight in 10% formalin. The tissue was then put in 25% sucrose (in 0.1M phosphate buffered saline-PBS) for cryoprotection and resectioned at 60 microns on a freezing microtome. Free-floating sections were rinsed in PBS, blocked, incubated in biotinylated anti-Lucifer-yellow antibody followed by incubation in ABC and visualization with DAB. The tissue was mounted on gelatin-subbed slides and coverslipped. Under a 100× objective and using a drawing tube, four neurons each from CA1 and the dorsal blade of the dentate gyrus were drawn and the spines counted.
- Synaptophysin Immunoreactivity.
- Slides containing sections through the dorsal hippocampus were incubated with the mouse monoclonal antibody to synaptophysin followed by incubation with a biotinylated secondary antibody, an ABC solution and then visualized using DAB (E. Masliah et al.,Exp. Neurol. 113, 131 (1991)). Following coverslipping, images of the stratum radiatum and molecular layers of the dentate were grabbed using an MTI camera and the imaging program Image 1 NIH Image 1.63 was used to analyze the density of synaptophysin staining in each of these areas.
- Table 1 below shows that there is no difference in the optical density of SYN-IR for the molecular layers of the dorsal blade of the dentate gyrus.
TABLE 1 inner molecular middle molecular outer molecular GROUP layer layer layer APOE3 SHAM 44.92 ± 7.8 37.50 ± 6.8 42.95 ± 5.1 APOE3 OVX 49.60 ± 5.6 42.50 ± 5.0 45.90 ± 4.5 APOE4 SHAM 46.10 ± 5.7 33.40 ± 5.0 42.50 ± 7.1 APOE4 OVX 48.96 ± 4.1 37.20 ± 3.0 44.37 ± 4.3 - FIG. 1 shows that there is no difference in spine density in the dorsal blade of the dentate gyrus in ApoE3 as compared to ApoE4 mice, comparing Sham OVX and OVX mice. FIG. 2 illustrates that CA1 apical dendrite spine density is significantly decreased in female ApoE4 mice deprived of estrogen. FIG. 3 shows that stratum radiatum synapthophysin immunoreactivity is significantly decreased in ApoE4 mice deprived of estrogen.
- Observations.
- (1) With our paradigm, mice carrying the APOE4 gene had a significant decrease in spine density on the apical dendrites of CA1 pyramidal neurons when compared to sham OVX sibs. In contrast, mice carrying the APOE3 gene had no change in spine density of CA1 pyramidal neurons when compared to sham OVX sibs. (2) Mice carrying the APOE4 gene had a significant decrease in the density of SYN-IR in the stratum radiatum when compared to sham OVX sibs. In contrast, mice carrying the APOE3 gene had no change in the density of SYN-IR in the stratum radiatum when compared to sham OVX sibs. (3) Mice carrying the APOE3 and E4 gene had no change in spine density of dorsal blade dentate granule cells when compared to sham OVX sibs. (4) Mice carrying the APOE3 and E4 gene had no change in the density of SYN-IR in the molecular layer of the dentate when compared to sham OVX sibs.
- These data show that the most vulnerable population of neurons is the CA1 neurons in the aging APOE4 mice deprived of estrogens. The decrease in both spine and SYN-IR density indicate a significant decrease in synapses and in neuronal connectivity. The interaction of the two risk factors, APOE4 and estrogen deprivation, exacerbates the pathology associated with AD.
- The foregoing is illustrative of the invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.
Claims (25)
1. A method of screening a human female subject for risk of developing Alzheimer's disease, comprising:
(a) determining the presence of at least one ApoE4 allele in a subject, and
(b) determining the presence or absence of decreased estrogen levels in said subject;
the presence of at least one ApoE4 allele in combination with decreased estrogen levels in said subject indicating said subject is at greater risk of developing Alzheimer's disease.
2. A method according to claim 1 , wherein said step of determining the presence of at least one ApoE4 allele is carried out by collecting a biological sample containing DNA from said subject, and then detecting the presence or absence of DNA encoding ApoE4 in said biological sample.
3. A method according to claim 2 , wherein said detecting step is carried out by amplifying DNA encoding ApoE4.
4. A method according to claim 1 , wherein said step of determining the presence of at least one ApoE4 allele is carried out by collecting an ApoE sample from said subject, and then detecting the presence or absence of the ApoE4 isoform in said ApoE sample.
5. A method according to claim 1 , wherein said subject has previously been determined to have one or more factors indicating that such subject is afflicted with Alzheimer's disease.
6. A method according to claim 1 , wherein said determining step comprises detecting whether said subject is homozygous for the gene encoding ApoE4.
7. A method for screening a human female subject for responsiveness to estrogen replacement therapy for the treatment of Alzheimer's disease, comprising:
determining the presence of at least on ApoE4 allele in said subject, wherein the presence of at least one apoE4 gene allele indicates said subject will receive greater benefit from estrogen replacement therapy that a subject who does not carry at least one ApoE4 allele.
8. A method according to claim 7 , wherein said step of determining the presence of at least one ApoE4 allele is carried out by collecting a biological sample containing DNA from said subject, and then detecting the presence or absence of DNA encoding ApoE4 in said biological sample.
9. A method according to claim 8 , wherein said detecting step is carried out by amplifying DNA encoding ApoE4.
10. A method according to claim 7 , wherein said step of determining the presence of at least one ApoE4 allele is carried out by collecting an ApoE sample from said subject, and then detecting the presence or absence of the ApoE4 isoform in said ApoE sample.
11. A method according to claim 7 , wherein said subject has previously been determined to have one or more factors indicating that such subject is afflicted with Alzheimer's disease.
12. A method according to claim 7 , wherein said determining step comprises detecting whether said subject is homozygous for the gene encoding ApoE4.
13. A method for treating a human female subject for Alzheimer's disease, comprising:
(a) determining the presence of at least on ApoE4 allele in said subject; and then
(b) administering estrogen replacement therapy to said subject in an Alzheimer's disease treatment effective amount.
14. A method according to claim 13 , wherein said administering step is carried out by orally administering an estrogenic agent to said subject.
15. A method according to claim 13 , wherein said administering step is carried out by transdermally administering an estrogenic agent to said subject.
16. A method according to claim 13 , wherein said estrogen replacement therapy includes the step of administering a progestationally active compound to said subject in an amount effective to inhibit estrogenic endometrial proliferation.
17. A method according to claim 13 , wherein said step of determining the presence of at least one ApoE4 allele is carried out by collecting a biological sample containing DNA from said subject, and then detecting the presence or absence of DNA encoding ApoE4 in said biological sample.
18. A method according to claim 17 , wherein said detecting step is carried out by amplifying DNA encoding ApoE4.
19. A method according to claim 13 , wherein said step of determining the presence of at least one ApoE4 allele is carried out by collecting an ApoE sample from said subject, and then detecting the presence or absence of the ApoE4 isoform in said ApoE sample.
20. A method according to claim 13 , wherein said subject has previously been determined to have one or more factors indicating that such subject is afflicted with Alzheimer's disease.
21. A method according to claim 13 , wherein said determining step comprises detecting whether said subject is homozygous for the gene encoding ApoE4.
22. A method of treating a human female subject for Alzheimer's disease, said method comprising the steps of:
selecting a subject that carries at least on ApoE4 allele, and then
administering estrogen replacement therapy to said subject in an Alzheimer's disease treatment effective amount.
23. A method according to claim 22 , wherein said administering step is carried out by orally administering an estrogenic agent to said subject.
24. A method according to claim 22 , wherein said administering step is carried out by transdermally administering an estrogenic agent to said subject.
25. A method according to claim 22 , wherein said estrogen replacement therapy includes the step of administering a progestationally active compound to said subject in an amount effective to inhibit estrogenic endometrial proliferation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/180,669 US20020192725A1 (en) | 1999-10-22 | 2002-06-26 | Relation of apolipoprotein E genotype and estrogen deprivation in alzheimer's disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/425,650 US6432643B1 (en) | 1999-10-22 | 1999-10-22 | Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels |
US10/180,669 US20020192725A1 (en) | 1999-10-22 | 2002-06-26 | Relation of apolipoprotein E genotype and estrogen deprivation in alzheimer's disease |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/425,650 Continuation US6432643B1 (en) | 1999-10-22 | 1999-10-22 | Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020192725A1 true US20020192725A1 (en) | 2002-12-19 |
Family
ID=23687464
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/425,650 Expired - Fee Related US6432643B1 (en) | 1999-10-22 | 1999-10-22 | Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels |
US10/180,669 Abandoned US20020192725A1 (en) | 1999-10-22 | 2002-06-26 | Relation of apolipoprotein E genotype and estrogen deprivation in alzheimer's disease |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/425,650 Expired - Fee Related US6432643B1 (en) | 1999-10-22 | 1999-10-22 | Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels |
Country Status (3)
Country | Link |
---|---|
US (2) | US6432643B1 (en) |
AU (1) | AU2296801A (en) |
WO (1) | WO2001031064A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021142163A1 (en) * | 2020-01-07 | 2021-07-15 | Selonterra, Inc. | Treatment of alzheimer's disease |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008500368A (en) * | 2004-05-27 | 2008-01-10 | ミジェニックス コーポレイション | Disubstituted 17-iminoestrogenic compounds for cell protection |
US9335331B2 (en) * | 2005-04-11 | 2016-05-10 | Cornell Research Foundation, Inc. | Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject |
US7902147B2 (en) * | 2007-11-05 | 2011-03-08 | Duke University | Chronic lymphocytic leukemia prognosis and treatment |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5228717A (en) * | 1991-12-09 | 1993-07-20 | Chrysler Corporation | Wheel support bracket formed from sheet metal |
US5422119A (en) * | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
US5468736A (en) * | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
US5508167A (en) * | 1992-10-13 | 1996-04-16 | Duke University | Methods of screening for Alzheimer's disease |
US5565199A (en) * | 1995-02-07 | 1996-10-15 | Page; Elliot W. | Systems and methods for the synthesis of natural base steroidal hormones and more especially estrogens and progesterone and estrogen-like and progesterone-like compounds and their derivatives derived as phytohormones from herbaceous plants |
US5585370A (en) * | 1987-09-24 | 1996-12-17 | Jencap Research Ltd. | Hormone preparation and method |
US5735801A (en) * | 1994-08-25 | 1998-04-07 | Caillouette; James C. | Estrogen or estradiol need determination by vaginal acidity determination |
US5773220A (en) * | 1995-07-28 | 1998-06-30 | University Of Pittsburgh | Determination of Alzheimer's disease risk using apolipoprotein E and .alpha. |
US5916176A (en) * | 1994-08-25 | 1999-06-29 | Caillouette; James C. | Estrogen or estradiol need determination by vaginal or urethral acidity determination |
US5935781A (en) * | 1994-04-27 | 1999-08-10 | Mcgill University | Apolipoprotein E polymorphism and treatment of Alzheimer's disease |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5210081A (en) | 1992-02-26 | 1993-05-11 | American Home Products Corporation | Alkali metal 8,9-dehydroestrone sulfate esters |
WO1998043647A1 (en) | 1997-03-28 | 1998-10-08 | Massachusetts Institute Of Technology, Inc. | Regulation of amyloid precursor protein (app) expression by estrogenic compounds |
EP1025116A1 (en) | 1997-10-23 | 2000-08-09 | American Home Products Corporation | Estra-1,3,5(10)-triene-7alpha-thioethers |
-
1999
- 1999-10-22 US US09/425,650 patent/US6432643B1/en not_active Expired - Fee Related
-
2000
- 2000-10-16 WO PCT/US2000/041177 patent/WO2001031064A2/en active Application Filing
- 2000-10-16 AU AU22968/01A patent/AU2296801A/en not_active Abandoned
-
2002
- 2002-06-26 US US10/180,669 patent/US20020192725A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5422119A (en) * | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
US5585370A (en) * | 1987-09-24 | 1996-12-17 | Jencap Research Ltd. | Hormone preparation and method |
US5228717A (en) * | 1991-12-09 | 1993-07-20 | Chrysler Corporation | Wheel support bracket formed from sheet metal |
US5508167A (en) * | 1992-10-13 | 1996-04-16 | Duke University | Methods of screening for Alzheimer's disease |
US5468736A (en) * | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
US5935781A (en) * | 1994-04-27 | 1999-08-10 | Mcgill University | Apolipoprotein E polymorphism and treatment of Alzheimer's disease |
US5735801A (en) * | 1994-08-25 | 1998-04-07 | Caillouette; James C. | Estrogen or estradiol need determination by vaginal acidity determination |
US5916176A (en) * | 1994-08-25 | 1999-06-29 | Caillouette; James C. | Estrogen or estradiol need determination by vaginal or urethral acidity determination |
US5565199A (en) * | 1995-02-07 | 1996-10-15 | Page; Elliot W. | Systems and methods for the synthesis of natural base steroidal hormones and more especially estrogens and progesterone and estrogen-like and progesterone-like compounds and their derivatives derived as phytohormones from herbaceous plants |
US5773220A (en) * | 1995-07-28 | 1998-06-30 | University Of Pittsburgh | Determination of Alzheimer's disease risk using apolipoprotein E and .alpha. |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021142163A1 (en) * | 2020-01-07 | 2021-07-15 | Selonterra, Inc. | Treatment of alzheimer's disease |
CN114938633A (en) * | 2020-01-07 | 2022-08-23 | 赛隆特拉有限公司 | Treatment of alzheimer's disease |
Also Published As
Publication number | Publication date |
---|---|
US20020098481A1 (en) | 2002-07-25 |
US6432643B1 (en) | 2002-08-13 |
WO2001031064A2 (en) | 2001-05-03 |
AU2296801A (en) | 2001-05-08 |
WO2001031064A3 (en) | 2002-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Harris et al. | Breast cancer risk: effects of estrogen replacement therapy and body mass | |
SWIFT et al. | Fanconi's anemia: Inherited susceptibility to chromosome breakage in various tissues | |
Evans | Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II] | |
Lanoue et al. | Limb, genital, CNS, and facial malformations result from gene/environment‐induced cholesterol deficiency: further evidence for a link to sonic hedgehog | |
Heutink et al. | Hereditary frontotemporal dementia is linked to chromosome 17q21—q22: A genetic and clinicopathological study of three dutch families | |
Tang et al. | Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy | |
Krohn et al. | Molecular pathogenesis of euthyroid and toxic multinodular goiter | |
Pickard et al. | Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. | |
Keller et al. | Progesterone exposure prevents matrix metalloproteinase-3 (MMP-3) stimulation by interleukin-1α in human endometrial stromal cells | |
US6242421B1 (en) | Methods for preventing and treating Alzheimer's disease | |
Wallace et al. | Clomiphene citrate versus letrozole: molecular analysis of the endometrium in women with polycystic ovary syndrome | |
JPH11514327A (en) | Estrogen compositions and methods of neuroprotection | |
Herrmann et al. | Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 inhibitor—a report of 3 cases | |
Cohen et al. | General health management and long-term care of the renal transplant recipient | |
CA3073998A1 (en) | Improved treatment of atopic dermatitis with tradipitant | |
Assaggaf et al. | Prevention of phenytoin-induced gingival overgrowth by lovastatin in mice | |
LieSke et al. | Autosomal dominant polycystic kidney disease. | |
Hong-Goka et al. | Estrogen receptors α and β in choroid plexus epithelial cells in Alzheimer's disease | |
US6432643B1 (en) | Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels | |
WO1997036615A1 (en) | Regulation of vascular smooth muscle cell heme oxygenase-1 | |
Lim et al. | Uveitis in patients with multiple sclerosis in clinical trials of fingolimod: incidence, prevalence, and impact on disease course | |
Sun et al. | Clinical and genetic analysis of the ABCA4 gene associated retinal dystrophy in a large Chinese cohort | |
Hahn et al. | ATP6B1 gene mutations associated with distal renal tubular acidosis and deafness in a child | |
Müller et al. | Contribution of resident endoneurial macrophages to the local cellular response in experimental autoimmune neuritis | |
Pezzi et al. | Childhood Leber’s hereditary optic neuropathy (ND1/3460) with visual recovery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE;ASSIGNOR:DUKE UNIVERSITY;REEL/FRAME:021177/0226 Effective date: 20020918 |